This study is for children and young adults (ages 2-21) with acute leukemia that has come back or is not responding to treatment. It's looking for the safest and most effective dose of three medicines given together: ziftomenib (given intravenously, meaning into a vein), venetoclax (taken by mouth), and azacitidine (taken by mouth). These medicines are being tested in patients whose leukemia has specific genetic changes (KMT2A-r, NPM1-m, NUP98-r, or HOX pathway mutations). The main goal is to understand the safety and side effects of this combination. The study also aims to see how well the treatment works in shrinking the leukemia. This is a Phase I study, meaning it's an early-stage trial focused on finding the right dose.

Study design

This is a Phase I interventional study, which means participants will receive the study treatments. It plans to enroll 22 participants to find the safest dose of the drug combination.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Safety and side effects will be monitored throughout the study, which is expected to last an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.